IMPaCT 2.0

影响2.0

• 批准号: 9211898
• 负责人: Brian M. Rivers
• 金额: $ 7.81万
• 依托单位: MOREHOUSE SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9211898
• 关键词: Address; African American; Alabama; Belief; Cancer Burden; Cancer Center; Cancer Patient; Caring; Client satisfaction; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Trials; Communities; Comprehensive Cancer Center; Computer software; Conflict (Psychology); Cultural Backgrounds; Data; Data Element; Electronic Health Record; Eligibility Determination; Enrollment; Environment; Ethnic group; Evaluation; Fright; Healthcare; Hospitals; Institution; Interpersonal Relations; Intervention; Link; Malignant Neoplasms; Malignant neoplasm of prostate; Minority Participation; Modeling; Morehouse School of Medicine; Outcome; Patients; Pilot Projects; Pre-Post Tests; Race; Research; Research Infrastructure; Science; Self Efficacy; Social Characteristics; System; Tablets; Technology; Training; Trust; Underserved Population; United States; Universities; University of Alabama at Birmingham Cancer Center; Work; base; cancer clinical trial; cancer health disparity; design; health care service; health disparity; malignant breast neoplasm; medical specialties; member; primary outcome; programs; randomized trial; repository; research study; retention rate; safety net; satisfaction; screening; secondary outcome; success; willingness

7. PROJECT SUMMARY African Americans (AAs) are more likely to develop and die from cancer than any racial and ethnic group in the United States (U.S.). Over the past two decades, there has been an increased focus on participation of AAs in cancer clinical trials (CCTs) to address this disproportionate burden of cancer; however AAs continue to be underrepresented in CCTs. The dearth of AAs participating in CCTs diminishes the generalizability of results of trials. If AAs remain underrepresented in CCTs, the implications include slower progress in elucidating the underlying causes of long-standing health disparities in cancer outcomes. There is an extensive body of science detailing trial participation barriers among AAs, including limited access to specialty care centers where trials are conducted, competing work obligations, and fear and mistrust of clinical research. Despite these barriers, AAs are, inherently, no less willing to participate in CCTs or other types of research studies than other racial or ethnic groups. The absence of differences in willingness to participate suggests that persistent disparities in accrual may, in fact, be due to AAs being offered fewer opportunities than whites to participate in CCTs. Although many interventions have focused on approaches to increase the willingness of AAs to participate, perhaps efforts should be focused on increasing the opportunities among AAs to participate in CCTs. We propose to adapt the IMPaCT patient navigation model and pilot a clinical trials navigator program, IMPaCT 2.0, at Morehouse Healthcare (MH) and Grady Hospital (Grady), one of the largest safety-net hospitals in the nation. We propose to enhance the patient navigation model with a mobile tablet-based clinical trial tracking system (CTTS) (using i2b2 software) to facilitate increased engagement among AA patients regarding CCT participation opportunities and to address deficits in the research infrastructure at these two institutions. Utilizing a qualitative approach, we will identify those barriers and facilitators to AA recruitment at MH/Grady (Specific Aim 1) and incorporate those findings into an adapted clinical trials navigation (CTN) model with an integrated mobile tablet CTTS (Specific Aim 2)., We will implement IMPaCT 2.0 at MH/Grady breast and prostate cancer clinics and evaluate, in a one-group, pre-/post-test design, the feasibility and acceptability (Specific Aim 3).

7. 项目概要 非裔美国人 (AA) 比任何种族和族裔群体都更有可能患上癌症并死亡。 美国（美国）。在过去的二十年里，人们越来越关注 AA 的参与 癌症临床试验（CCT）以解决这种不成比例的癌症负担；然而 AA 仍然是 在 CCT 中代表性不足。参与 CCT 的 AA 的缺乏降低了结果的普遍性 试验。如果 AA 在 CCT 中的代表性仍然不足，其影响包括在阐明问题方面进展缓慢。 癌症结果长期存在健康差异的根本原因。有一个广泛的机构 科学详述了 AA 参与试验的障碍，包括进入专业护理中心的机会有限 进行试验的地点、相互竞争的工作义务以及对临床研究的恐惧和不信任。尽管 面对这些障碍，AA 本质上参与 CCT 或其他类型的研究的意愿并不比 其他种族或族裔群体。参与意愿不存在差异表明，持续的 事实上，应计收入的差异可能是由于 AA 的参与机会少于白人 相关色温。尽管许多干预措施都侧重于提高 AA 的意愿的方法 参与，也许应该努力增加 AA 参与的机会 相关色温。我们建议调整 IMPACT 患者导航模型并试行临床试验导航器计划， IMPACT 2.0，莫尔豪斯医疗保健 (MH) 和格雷迪医院 (Grady)，最大的安全网之一 全国的医院。我们建议通过基于移动平板电脑的临床增强患者导航模型 试验跟踪系统 (CTTS)（使用 i2b2 软件）促进 AA 患者的参与 关于 CCT 参与机会并解决这两个机构研究基础设施的缺陷 机构。利用定性方法，我们将确定 AA 招聘的障碍和促进因素 MH/Grady（具体目标 1）并将这些发现纳入改编的临床试验导航 (CTN) 具有集成移动平板电脑 CTTS 的模型（具体目标 2）。，我们将在 MH/Grady 实施 IMPACT 2.0 乳腺癌和前列腺癌诊所，并在一组测试前/测试后设计中评估可行性和 可接受性（具体目标 3）。